N²-isopropylpyridine-2,5-diamine | 52025-41-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N²-isopropylpyridine-2,5-diamine
• 英文别名: N~2~-isopropyl-2,5-pyridinediamine；2-N-propan-2-ylpyridine-2,5-diamine
• CAS: 52025-41-9
• 化学式: C₈H₁₃N₃
• mdl: MFCD09047761
• 分子量: 151.211
• InChiKey: GIFWHQBUBNUEBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  50.9
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  N²-isopropylpyridine-2,5-diamine 在 盐酸 、 copper(ll) sulfate pentahydrate 、 sodium ascorbate 、 N,N-二异丙基乙胺 、 sodium nitrite 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 反应 18.5h， 生成 4-(1-(6-(isopropylamino)pyridin-3-yl)-1H-1,2,3-triazol-4-yl)benzoic acid
  参考文献：
  名称：

  Hit-to-lead optimization of a latency-associated nuclear antigen inhibitor against Kaposi’s sarcoma-associated herpesvirus infections

  摘要：

  The Latency-associated nuclear antigen (LANA) plays a central role for the latent persistence of the Kaposi's Sarcoma Herpesvirus (KSHV) in the human host and helps to establish lifelong infections. Herein, we report our efforts towards hit-to-lead generation starting from a previously discovered LANADNA inhibitor. By tethering the viral genome to the host nucleosomes, LANA ensures the segregation and persistence of the viral DNA during mitosis. LANA is also required for the replication of the latent viral episome during the S phase of the cell cycle. We aim to inhibit the interaction between LANA and the viral genome to prevent the latent persistence of KSHV in the host organism. Medicinal chemistry-driven optimization studies and structure-activity-relationship investigation led to the discovery of an improved LANA inhibitor. The functional activity of our compounds was evaluated using a fluorescence polarization (FP)-based interaction inhibition assay and electrophoretic mobility shift assay (EMSA). Even though a crystal structure of the ligand protein complex was not available, we successfully conducted hit optimization toward a low micromolar protein-nucleic acid-interaction inhibitor. Additionally, we applied STD-NMR studies to corroborate target binding and to gain insights into the binding orientation of our most potent inhibitor, providing opportunities for further rational design of more efficient LANAtargeting anti KSHV agents in future studies. (C) 2020 The Author(s). Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2020.112525
• 作为产物：
  描述：

  2-溴-5-硝基吡啶 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 18.0h， 生成 N²-isopropylpyridine-2,5-diamine
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  [FR] COMPOSÉS ET PROCÉDÉS POUR LA MODULATION DES KINASES ET LEURS INDICATIONS

  摘要：

  化合物的结构式I描述了对蛋白激酶具有活性的化合物，以及使用这些化合物治疗与蛋白激酶异常活性相关的疾病和症状的方法。其中Ar是可选择取代的杂芳基；R2是氢、低碳基或卤素；U选自由-S(O)2-、-C(X)-、-C(X)-N(R10)-和-S(O)2-N(R10)-组成的群；R3是可选择取代的低碳基、可选择取代的C3.6环烷基、可选择取代的杂环烷基、可选择取代的芳基或可选择取代的杂芳基；其中R1、R3、R4、m、L1、X和R10如本文所述。

  公开号：

  WO2009012283A1

文献信息

• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Wu Guoxian

  公开号：US20100190777A1

  公开（公告）日：2010-07-29

  Compounds of formula I active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Formula (I) wherein Ar is optionally substituted heteroaryl; R 2 is hydrogen, lower alkyl or halogen; U is selected from the group consisting of —S(O) 2 —, —C(X)—, —C(X)—N(R 10 )—, and —S(O) 2 —N(R 10 )—; R 3 is optionally substituted lower alkyl, optionally substituted C3.6 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; and wherein R 1 , R 3 , R 4 , m, L 1 , X R 10 are as described herein.

  本文描述了公式I的化合物对蛋白激酶的活性，以及使用这些化合物治疗与蛋白激酶异常活性相关的疾病和病况的方法。公式（I）中，Ar是可选的取代杂环芳基；R2是氢、低碳基或卤素；U选自由基组，包括—S（O）2—、—C（X）—、—C（X）—N（R10）—和—S（O）2—N（R10）—；R3是可选的取代低碳基、可选的取代C3.6环烷基、可选的取代杂环烷基、可选的取代芳基或可选的取代杂环芳基；其中R1、R3、R4、m、L1、X和R10如本文所述。
• Compounds and methods for kinase modulation, and indications therefor
  申请人：Plexxikon Inc.

  公开号：US10426760B2

  公开（公告）日：2019-10-01

  Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

  本文介绍了对蛋白激酶有活性的化合物，以及使用这些化合物治疗与蛋白激酶活性异常有关的疾病和病症的方法。
• 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
  申请人：PLEXXIKON, INC.

  公开号：EP2170830B1

  公开（公告）日：2014-10-15
• US9469640B2
  申请人：——

  公开号：US9469640B2

  公开（公告）日：2016-10-18
• US9844539B2
  申请人：——

  公开号：US9844539B2

  公开（公告）日：2017-12-19